← Return to Issues with ProACT incontinence value
DiscussionIssues with ProACT incontinence value
Prostate Cancer | Last Active: Sep 21 11:34am | Replies (27)Comment receiving replies
Replies to "I mentioned a new drug being studied that would seek out dormant and alive cancer cells..."
That looks as I recall seeing it.
Now I’m enjoying reading replies to you and the study you linked
The way info travels here give me opportunity to as my oncologist. Depending if Jekyll or Hyde shows up there exists an opportunity to speak to a Doctor, VERY RESPECTED in the field of PC oncology. If he knows about this drug and he’s in THE GOOD MOOD he’ll engage me in an intellectual discussion
If he 1 didn’t sleep well or if a resent double hip replacement and his personal philosophy on PAIN MEDS sympathy and empathy isn’t enough to bring a smile to his face. I listen and he share his pain. I make him laugh from time to time with “ we got this Doc with an arm around his shoulders or a light fist bump; something about TREATING him like “ one of the guys “ tickles his funny brain ( like a funny bone but in the head so I’m thinking it might be a MENSA inside joke. Great to hear him laugh but at times he laughs too fast then he starts choking… then I lightly pat him on the back. I’ve printed up a bill that I plan on handing to him with charges for services rendered. The charge: a🦌too98
PS this is a side effect of one of the drugs you gave me or maybe it’s the new 🌻that I procured from the dispensary
Read the article and got the impression that this drug is NOT a radio pharmaceutical drug like Pluvicto. Is that correct?
Updated: I read the following about this drug - ARV-766, also known as luxdegalutamide, is an investigational oral drug developed by Arvinas for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It belongs to a class of drugs called proteolysis-targeting chimeras (PROTACs), which are designed to selectively degrade specific proteins within cells.